ANZCTR search results

The heart can be stimulated to change its size and shape. The heart changing size and shape is a normal adaptation; however, in certain cases this adaptation can become harmful. Change in heart structure predicts heart events (eg. congestive heart failure, abnormal heart beats). Heart size and shape varies considerably between people; it is currently unknown what accounts for most of this variability. Previous studies suggest a genetic contribution; however, no studies have yet identified the specific changes in a person’s genetic makeup which explain why one person has a bigger heart than another. This study aims to identify rare variants in specific genes that are related to abnormal changes in heart structure. This study will do so by tracking changes in heart structure related to endurance exercise training as well as normal aging. Endurance athletes with the greatest change in heart structure will have select genes compared to endurance athletes with the least change in heart structure after 2 years of training. Additionally these gene profiles will be compared to non-endurance athletes who have the greatest and least change in heart structure over a 2-year period. In this way investigators can identify which gene variants are related to highly adaptive versus less adaptive hearts. Identifying gene variants related to heart size may help identify individuals at risk of abnormalities in which the heart enlarges too much. Identifying at-risk individuals allows doctors to identify people who may benefit from advice or treatments that may prevent problems from developing.

Short title EnRICH Protocol number and date X16-0447 dated 29/03/2017 This study aims to assemble a patient cohort to describe the natural history of and patterns of care for lung cancer; identify current gaps in evidence and practice for clinical quality improvement. Who is it for? You may be eligible for this study if you are aged 18 or over and have a diagnosis of lung cancer and are attending a defined clinical site for diagnosis or treatment. Study details All participants will provide demographic information, and their medical records will be used to build a profile of the participant’s cancer, including clinical and outcome information. Participants will also provide around 3 blood samples for research taken at the time of routine collection (e.g. prior to commencement of treatment, post-treatment). Biopsied tumour samples will be used to screen for biomarkers and molecular signals of disease. This research will assemble a patient cohort for identifying current gaps in evidence and practice, creating a platform for researchers across the translational research spectrum to develop and initiate studies to address these gaps.

Atrial fibrillation (AF) is the most common sustained heart rhythm problem that increases the chance of stroke and heart failure and currently represents a growing socioeconomic burden in our ageing population. Amongst the established risk factors of age, hypertension and diabetes, exercise is increasingly recognised as a powerful modulator of AF risk. Low and moderate intensity exercise is an important therapy in the prevention and treatment of AF but, at the other end of the spectrum, intense endurance exercise has been associated with a 5-fold increase in AF risk. The reasons for this excess are not known but may relate to the profound atrial remodelling that occurs with endurance athletic training. The rate at which AF occurs in retired elite endurance athletes will be compared with non-athletes who are matched for health status, age and gender. We will assess the extent to which exercise-induced changes in heart shape, function and electrical properties represent a short-term or permanent process. This will be assessed by comparing three groups: (1) young athletes adapting to elite training, (2) middle-aged athletes during end of career detraining, and (3) retired athletes with more than 10 years of competition at national or international level. A group of athletes with arrhythmias will also provide a meaningful comparison group to determine which characteristics are shared amongst groups. To study the changes in heart structure and function we will use the latest echocardiographic and cardiac magnetic resonance imaging techniques. The study is being conducted by a team of researchers at St Vincent's Institute of Medical Research, the South Australian Health and Medical Institute and a research team in Belgium led by A/Professor Andre La Gerche.

Intermittent pneumatic compression (IPC) has been widely used as a means to prevent venous thromboembolism in hospitalised patients. Whether IPC should be considered different from thromboembolic deterrent stockings and is not contraindicated in patients with peripheral-limb vascular insufficiency is uncertain. This study assesses whether (1) IPC can improve peripheral-limb muscle tissue oxygenation (StO2), and (2) a sequential-compressions mode is better than a single-compartment compression in improving StO2. Twenty volunteers will be randomised to have their left or right arm treated with a sequential or single-compartment IPC for 10 minutes, using the contralateral arm without IPC as an intra-participant control. After a 5-min wash-out period, the procedure is repeated on the same arm using the alternative mode of IPC. StO2 on the hand thenar muscle is monitored every 2-min for 10-min using a near infra-red spectroscopy tissue oxygen saturation monitor.

This study aims to assess the usability of a breathing platform for relaxation. Healthy participants will be used and required to fill in questionnaires during and at the completion of the study based on the ease of use of the system.

Soluble fibre is a source of plasma short chain fatty acids (SCFA), which are known to have antiinflammatory properties. This study will investigate the plasma short chain fatty acid (SCFA) yield over 10 hours following consumption of two different oligosaccharide blends in healthy adult males and females. This information will be used in the design of future clinical intervention trials.

Purpose of study Extra virgin olive oil, a key ingredient of the cardioprotective Mediterranean diet, is considered a healthy source of dietary fat due to its high content of monounsaturated fatty acids and antioxidant polyphenols. However, while consistent, promising evidence exists, the unique contribution of polyphenols to the cardioprotective effect of olive oil is not fully established. This study will examine the effect of high-polyphenol extra virgin olive oil versus low-polyphenol olive oil on markers of cardiovascular disease risk that are related to cholesterol metabolism and total antioxidant capacity as well as measures of cognitive function. Hypothesis: Compared with a low polyphenol olive oil, a high polyphenol olive oil intervention will result in improved measures of HDL cholesterol efflux and total antioxidant capacity in a healthy adult population. Objectives 1. Efficacy. Efficacy outcomes include HDL cholesterol efflux, total antioxidant capacity, cholesterol levels (total, HDL, LDL, triglycerides), cognitive performance, and blood pressure. 2. Safety. Safety outcomes include adverse and serious adverse events directly attributable to the intervention period. 3. Adherence. Adherence outcomes will include biomarkers related to monounsaturated fat intake, bottle count, self-report checklist, and patient interview.

Diabetic neuropathy is the most common complication of diabetes mellitus, affecting >50% of individuals with the condition. The Diabetes Control and Complications Trial demonstrated that intensive blood glucose control could reduce the incidence of neuropathy and potentially slow progressive nerve damage; however, there are currently no clinical therapies for attenuating the onset or progression of neuropathy. Omega-3 supplements have potential general health benefits, however their effect on peripheral nerves is currently unknown. There is growing scientific evidence that dietary supplementation with omega-3 essential fatty acids, may be of benefit in improving peripheral nerve integrity. This randomised, double-masked, placebo-controlled clinical trial to assess the effects of a six-month period of supplementation with omega-3 PUFAs on small nerve fibre structure and function, measured both in the eye and the extremities of the body, in individuals with type-1 diabetes. The effects omega-3 supplements will be compared with a control group, who will consume an olive oil supplement. If shown to be effective, omega-3 supplements could be an adjuvant therapy (additional to achieving optimal glucose control), for treating diabetic neuropathy, for which there are currently no other treatments.

To date, randomized clinical trials have only assessed the efficacy of single-nutrient supplementation in early psychosis. Research in other populations has indicated that combining various nutrients within multi-ingredient ‘nutraceuticals’ can result in greater benefits for mental health than single-nutrient supplementation, and is less likely to cause nutritional imbalances. This project will be the first internationally to assess the feasibility and efficacy of a multi-ingredient nutraceutical for treating young people with early psychosis. The novel formula contains a range of food-derived nutrients including vitamins, minerals, antioxidants and amino-acids. Each of these nutrients, in isolation, have already been indicated as potentially effective adjunct treatments for mental health conditions, perhaps through restoring nutritional deficiencies, and targeting abnormal brain processes implicated in the disorders. We hypothesize that combining these nutrients within a single nutraceutical, and administering this in early illness (when nutrients are most effective), may present a novel adjunctive treatment for improving outcomes of early psychosis. This pilot study will assess the feasibility and effectiveness of a multi-ingredient nutraceutical, designed to act as an adjunctive with standard antipsychotic treatment, in order to improve physical and mental health outcomes in people with early psychosis. Specifically, we will be performing a randomized controlled trial to test the hypothesis that adjunctive treatment with a nutrient-enriched fruit flavoured drink mix can reduce negative symptoms in young people with early psychosis.

This study will examine the effect of wound debridement frequency on the healing of foot ulcers in people with diabetes. The study will take place in up to 2 different sites, the Diabetes Centre High Risk Foot Service at Royal Prince Alfred Hospital (RPAH) and the High Risk Foot Service at Concord General Repatriation Hospital (CGRH). Foot ulcers most often develop because diabetes can cause damage to the nerves and/or blood vessels of the feet. An important part of treatment is a procedure called debridement. This is when the Podiatrist or the Nurse removes hard skin from the edge of the ulcer and unhealthy tissue, called slough or necrotic tissue, from the base of the ulcer. This is done using a scalpel blade and/or curette and/or forceps; each are special instruments to help to remove unhealthy tissue. While debridement is considered best practice and is performed safely and with good effect on wound healing, and is part of the standard care patients recieve at this service, there is very limited evidence to tell us how often this should be done and whether the frequency with which it is done affects how the ulcer heals. The purpose of this study is therefore to look at whether debridement performed on a weekly basis versus every 2 weeks affects the healing of diabetes-related foot ulcers. As of April 2018, there are 5 participating treatment sites; Concord, Royal Prince Alfred Hospital, St George Hospital, John Hunter and Bankstown Hospitals. Northern Sydney Hospitals, Royal North Shore and Hornsby have submitted site specific approval to become additional sites for this study.